INMD — InMode Ltd.

Summary of InMode Ltd. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $103.9 million, up from $97.9 million in Q4 2024.
• Full Year 2025 Revenue: $370.5 million, a 6% decrease from 2024.
• International Sales: Q4 international sales reached $48.5 million (47% of total sales), a 38% increase year-over-year, primarily driven by Europe.
• Gross Margins: GAAP gross margins were 78% (79% in 2024). Non-GAAP gross margins were consistent at 79%.
• Operating Expenses: GAAP operating expenses rose significantly to $55.3 million in Q4, reflecting an 110.5% increase year-over-year.
• Earnings Per Share: GAAP diluted EPS was $0.42 in Q4 (down from $1.14 in 2024). Non-GAAP diluted EPS was $0.46, up from $0.42 in Q4 2024.
• Cash Position: As of December 31, 2025, cash and equivalents totaled $555.3 million, with $127.4 million returned to shareholders via share repurchases.

2. Strategic Updates and Business Highlights

• Leadership Changes: Michael Dennison appointed as President of North America; operations unified across the U.S. and Canada.
• Sales Force Restructuring: Segmented sales teams focused on aesthetics and wellness, with a specialized team for the Envision platform.
• Product Innovation: Launched CO2 laser platforms in 2025; plans to introduce two new platforms in 2026, including a Pico laser and a combined Morpheus technology with Erbium YAG laser.
• Focus on Minimally Invasive Technology: 76% of Q4 revenue came from minimally invasive platforms.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $365 million and $375 million, with non-GAAP gross margins projected between 75% and 77%.
• Operating Income Guidance: Non-GAAP income from operations anticipated between $87 million and $92 million, with non-GAAP diluted EPS expected between $1.43 and $1.48.
• Stabilization Year: Management views 2026 as a year for stabilization following a challenging 2025.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Total revenue decreased by 6% year-over-year, indicating ongoing challenges in the aesthetic market.
• Operating Margin Pressure: Non-GAAP operating margins fell to 26% in 2025 from 33% in 2024, primarily due to increased sales and marketing expenses.
• Market Conditions: Demand in North America remains below historical levels, with competition and economic factors impacting sales.
• Product Margin Concerns: New laser products are expected to have lower gross margins, which could further pressure overall profitability.

5. Notable Q&A Insights

• Encouraging Signs: Management noted slight increases in procedure numbers and consumables, alongside declining interest rates, as potential positive indicators for future growth.
• Strategic Alternatives: The Board is exploring strategic alternatives to enhance company value, including a recent inquiry from Steel Partners regarding a potential acquisition.
• Clinical Studies: Plans for clinical studies related to women's health and dry eye indications are underway, with expected FDA timelines extending into 2027.
• Market Dynamics: The introduction of GLP-1 medications is shifting consumer preferences towards non-invasive treatments, impacting the demand for minimally invasive procedures.

Overall, while InMode Ltd. is navigating a challenging market environment, it is positioning itself for future growth through leadership changes, product innovation, and a focus on operational efficiency.